Literature DB >> 3663498

Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice.

L P Ormerod1, N Horsfield.   

Abstract

One hundred and twenty-four patients have been treated with 6-month regimens for pulmonary and pleural tuberculosis over 5 years; 118 patients have completed treatment as planned. No patient has relapsed of the 109 followed up for 15 months from the end of chemotherapy, or in the remaining nine patients still under observation. Significant drug side effects requiring alteration of treatment occurred in only three patients. Six-month regimens in routine practice are well tolerated and are highly effective.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663498     DOI: 10.1016/0007-0971(87)90160-4

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  3 in total

1.  Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.

Authors:  Brandon C Rosen; Nicholas A Dillon; Nicholas D Peterson; Yusuke Minato; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.

Authors:  Nicholas A Dillon; Nicholas D Peterson; Brandon C Rosen; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

3.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.